Editorial: microRNAs for the diagnosis of fatty liver disease in the population-are we inching closer towards the target? Authors' reply
- PMID: 33616986
- DOI: 10.1111/apt.16234
Editorial: microRNAs for the diagnosis of fatty liver disease in the population-are we inching closer towards the target? Authors' reply
Comment on
-
Editorial: microRNAs for the diagnosis of fatty liver disease in the population-are we inching closer towards the target?Aliment Pharmacol Ther. 2021 Feb;53(4):557-558. doi: 10.1111/apt.16219. Aliment Pharmacol Ther. 2021. PMID: 33616998 No abstract available.
References
REFERENCES
-
- Ma AT, Ginès P. Editorial: microRNAs for the diagnosis of fatty liver disease in the population – are we inching closer towards the target? Aliment Pharmacol Ther. 2021;53:557–558.
-
- Zhang X, Mens MMJ, Abozaid YJ, et al. Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. Aliment Pharmacol Ther. 2021;53:432–442.
-
- Tapper EB, Saini SD, Sengupta N. Extensive testing or focused testing of patients with elevated liver enzymes. J Hepatol. 2017;66:313‐319.
-
- Ekstedt M, Franzén LE, Mathiesen UL, et al. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865‐873.
-
- Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA‐based Covid‐19 vaccine candidates. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2027906
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical